Clinical Trial

Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial

Study acronym: FORAT
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Objective: to evaluate the efficacy and safety of intra-arterial intrathrombus administration of the recombinant non-immunogenic staphylokinase (Fortelyzin®) in patients with acute limb ischemia (ALI) vs surgery.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-05-12; most recent amendment 2025-11-27.
Status change: Not Yet Recruiting → Recruiting 2023-01-19
Trial Details
NCT Number NCT05372718
Lead Sponsor Supergene, LLC
Conditions Acute Limb Ischemia
Enrollment 170 participants
Start Date 2022-12-26
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-01